In a phase 2 RCT in 115 participants with progressive MS, oral lipoic acid did not slow 24-month decline in walking speed vs placebo (-0.39 vs -0.30 ft/sec). Lipoic acid caused more proteinuria and more dropouts (37% vs 17%).
RCTn = 115
Spain et al. Lipoic Acid for Treatment of Progressive Multiple Sclerosis: A Phase 2 Randomized Clinical Trial